Brain Endothelium - TARgeted Gene therapy to improve Aβ clearance in Alzheimer’s Disease

Project description

Gene therapy for Alzheimer’s disease

Despite extensive research into Alzheimer’s disease (AD), current treatment options are limited and only achieve a slight delay in the clinical decline. Therefore, novel approaches are needed that halt cognitive decline and disease progression. Funded by the Marie Skłodowska-Curie Actions programme, the BEndTarG project proposes an alternative intervention that aims to clear the amyloid-beta plaques, one of the hallmarks of AD. Researchers will develop nanocarriers engineered to specifically target brain endothelial cells and capable of reaching the blood-brain barrier. The nanocarriers will contain genes that enhance amyloid-beta clearance as a novel gene therapy strategy for AD.

Fields of science

• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• medical and health sciences › medical biotechnology › genetic engineering › gene therapy
• medical and health sciences › basic medicine › physiology › pathophysiology

Programme(s)

• HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme

Topic(s)

• HORIZON-MSCA-2021-PF-01-01 - MSCA Postdoctoral Fellowships 2021

Call for proposal

HORIZON-MSCA-2021-PF-01

See other projects for this call

Funding Scheme

HORIZON-AG-UN - HORIZON Unit Grant

Coordinator

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Net EU contribution

€ 165 312,96

Address

Carrer Baldiri Reixac Planta 2a 10-12
08028 Barcelona
Spain

Region

Este › Cataluña › Barcelona

Activity type

Research Organisations

Links

Other funding

No data